OR WAIT null SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Promising Results Pave the Way to Inhaled TB Vaccine
ePT--the Electronic Newsletter of Pharmaceutical Technology
Scientists at the University of North Carolina at Chapel Hill have successfully tested a new inhaled tuberculosis (TB) vaccine.
Chapel Hill, NC (Mar. 14)-Scientists at the University of North Carolina at Chapel Hill successfully tested a new inhaled tuberculosis (TB) vaccine. The drug was a Bacillus Calmet-Guerin (BCG) vaccine, which is used worldwide to protect more than 100 million infants annually.
Led by Tony Hickey, PhD, the research team developed a dry-powder formulation for inhalation that they report is just as effective as the traditional vaccine. Because the drug is made using spray drying instead of freeze-drying, the powder does not require refrigeration or clean water for reconstitution, which is an advantage in developing countries.
In a university press release, Hickey states that “breathing in a TB vaccine is beneficial because inhalation is the way tuberculosis is contracted.” In addition, he notes, “The results of this study are very exciting because there are other bacterial vaccines being developed that might benefit from this technology.”
